Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP02 Telaprevir
D09012 Telaprevir (JAN/USAN/INN)
Drug groups [BR:br08330]
Antiviral
DG03198 Anti-HCV agent
DG02001 HCV NS3/4A protease inhibitor
D09012 Telaprevir
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D09012 Telaprevir
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
D09012 Telaprevir
DG01915 CYP3A5 inhibitor
D09012 Telaprevir
Transporter inhibitor
DG01622 ABCB1 inhibitor
D09012 Telaprevir
DG02865 SLCO1B1 inhibitor
D09012 Telaprevir
Antimicrobials [BR:br08307]
Antivirals
Polyprotein cleavage inhibitor
HCV NS3/4A inhibitor
D09012 Telaprevir (JAN/USAN/INN)
Antimicrobials abbreviations [BR:br08327]
Antivirals
Polyprotein cleavage inhibitor
HCV NS3/4A inhibitor
D09012 Telaprevir (JAN/USAN/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09012
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09012
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09012
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09012
Drug transporters
D09012